Parkinson's disease: a novel MRI method for determining structural changes in the substantia nigra

OBJECTIVES To use MRI in a novel way to image and quantify the changes occurring in the substantia nigra in Parkinson's disease. METHODS Six patients with idiopathic Parkinson's disease were compared with six age matched control subjects. The subjects were imaged using a combination of pulse sequences hypothesised to be sensitive to cell loss. RESULTS The images showed patterns of change in patients with Parkinson's disease. Highly significant differences between the patients and control population were found (p<0.001). CONCLUSIONS This methodology suggests the possibility of detecting presymptomatic disease in those judged to be at risk, and also in confirming the diagnosis in patients with early disease. Furthermore, the technique seems to hold promise as a means for staging the disease, and possibly differentiating other forms of parkinsonism.

[1]  D. Calne,et al.  The use of PET in Parkinson's disease. , 1995, Brain and cognition.

[2]  Robert B. Innis,et al.  Iodine-123-β-CIT and Iodine-123-FPCIT SPECT Measurement of Dopamine Transporters in Healthy Subjects and Parkinson's Patients , 1998 .

[3]  A. Lees,et al.  Ageing and Parkinson's disease: substantia nigra regional selectivity. , 1991, Brain : a journal of neurology.

[4]  H. Rusinek,et al.  Functional magnetic resonance imaging of human brain activity in a verbal fluency task , 1998, Journal of neurology, neurosurgery, and psychiatry.

[5]  M. Polymeropoulos,et al.  Mapping of a Gene for Parkinson's Disease to Chromosome 4q21-q23 , 1996, Science.

[6]  G. Sawle The detection of preclinical Parkinson's disease: What is the role of positron emission tomography? , 1993, Movement disorders : official journal of the Movement Disorder Society.

[7]  K. Miyasaka,et al.  [Magnetic resonance imaging in Parkinson's disease--the evaluation of the width of pars compacta on T2 weighted image]. , 1992, Rinshō shinkeigaku Clinical neurology.

[8]  P. Boesiger,et al.  T2 relaxation time in patients with Parkinson's disease , 1993, Neurology.

[9]  G. Chazot,et al.  Clinical and electrophysiological phenotype of a homozygously duplicated Charcot-Marie-Tooth (type 1A) disease. , 1997, European neurology.

[10]  G. Sawle,et al.  Separating Parkinson's disease from normality. Discriminant function analysis of fluorodopa F 18 positron emission tomography data. , 1994, Archives of neurology.

[11]  D. Calne,et al.  The Use of Pet in Parkinsons-Disease , 1995, Brain and Cognition.

[12]  D. Brooks Motor disturbance and brain functional imaging in Parkinson's disease. , 1997, European neurology.

[13]  R. Ordidge,et al.  Assessment of relative brain iron concentrations using T2‐weighted and T2*‐weighted MRI at 3 Tesla , 1994, Magnetic resonance in medicine.

[14]  M. Pericak-Vance,et al.  Genetic Complexity and Parkinson's Disease , 1997 .

[15]  J. Degroot,et al.  Magnetic resonance imaging of the midbrain in Parkinson's disease , 1986, Annals of neurology.

[16]  R. Ordidge,et al.  Increased iron‐related MRI contrast in the substantia nigra in Parkinson's disease , 1995, Neurology.

[17]  J. Sá,et al.  [Importance of magnetic resonance in Parkinson disease. An analytic study of the pars compacta]. , 1990, Acta medica portuguesa.